Table 2 SARS-CoV-2 neutralizing antibody and T cell response.

From: Humoral and cellular immunity against different SARS-CoV-2 variants in patients with chronic kidney disease

Assay

All patients (n = 88)

KTRs

Prior infection

No (n = 69)

Yes (n = 19)

P value

No (n = 59)

Yes (n = 29)

P valuea

NAb detected

 Ancestral

62 (70.5)

51 (73.9)

11 (57.9)

0.255

39 (66.1)

23 (79.3)

0.226

 BA.2.2

52 (59.1)

42 (60.9)

10 (52.6)

0.602

25 (42.4)

27 (93.1)

 < 0.001

 BA.2.3.20

41 (46.6)

32 (46.4)

9 (47.4)

1.000

19 (32.2)

22 (75.9)

 < 0.001

 BA.5.2

37 (42)

28 (40.6)

9 (47.4)

0.610

17 (28.8)

20 (69.0)

0.001

 XBB.1

23 (26.1)

18 (26.1)

5 (26.3)

1.000

8 (13.6)

15 (51.7)

 < 0.001

 IGRA positive

52 (59.1)

42 (60.9)

10 (52.6)

0.602

31 (52.5)

21 (72.4)

0.106

 nAb not detectedb & IGRA negative

14 (15.9)

7 (10.1)

7 (36.8)

0.010

13 (22.0)

1 (3.4)

0.030

  1. Data are n (%).
  2. Abbreviations: IGRA, interferon gamma release assay; nAb, neutralizing antibody.
  3. aFisher’s exact test.
  4. bNeutralizing antibody not detected against ancestral strain, BA.2.2, BA.2.3.20, BA.5.2 and XBB.1.
Back to article page